| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Due to the paucity of patient derived models in rare cancers, identification of therapeutic targets remains challenging. We developed a patient derived model, CLF-PED-015-T, from a patient with an undifferentiated sarcoma. From this model, we performed pooled RNAi and CRISPR-Cas9 negative selection screens and integrated that with a small molecule screen. Integration of these data identified CDK4 and XPO1 as potential therapeutic targets.
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Cohort
- Total number of consented subjects: 1
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
No inclusion or exclusion criteria.
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Exome Sequencing Agilent SureSelect Human All Exon v.2 Kit N/A N/A Germline, Tumor and Cell line Whole Transcriptome Sequencing Illumina TruSeq N/A N/A Tumor and Cell line - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Sarcoma
- Links to Related Genes
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigators
- William C. Hahn, MD, PhD. Dana-Farber Cancer Institute, Boston, MA, USA.
- Jesse Boehm, PhD. Broad Institute, Cambridge, MA, USA.
-
Funding Source
- U01 CA176058. Dana-Farber Cancer Institute, Boston, MA, USA.
-
Principal Investigators